X0508 4 2026-02-17 0001581280 Twist Bioscience Corp TWST 0001755970 Finn Patrick John C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD. SOUTH SAN FRANCISCO CA 94080 false true false false President and COO 1 Common Stock 2026-02-17 4 M false 18205 23.33 A 324455 D Common Stock 2026-02-17 4 M false 32300 26.66 A 356755 D Common Stock 2026-02-17 4 S false 21858 50.321 D 334897 D Common Stock 2026-02-17 4 S false 16616 51.423 D 318281 D Common Stock 2026-02-17 4 S false 26952 52.686 D 291329 D Common Stock 2026-02-17 4 S false 3541 53.110 D 287788 D Stock Option (right to buy) 26.66 2026-02-17 4 M false 32300 0 D 2028-11-18 Common Stock 32300 0 D Stock Option (right to buy) 23.33 2026-02-17 4 M false 18205 0 D 2029-10-23 Common Stock 18205 0 D The transactions reported on this Form 4 were affected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 13, 2025. Represents the weighted average sales price per share. The shares sold at prices ranging from $50.00 to $50.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $51.00 to $51.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $52.00 to $52.99 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Represents the weighted average sales price per share. The shares sold at prices ranging from $53.01 to $53.25 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. The option is immediately exercisable. 12/60th of the shares subject to the option vest and become exercisable on October 31, 2019 and 1/60th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuous service through each vesting date. The option is immediately exercisable. 25% of the shares subject to the option vest and become exercisable on October 24, 2020 and 1/48th of the shares subject to the option vest and become exercisable on each monthly anniversary thereafter, subject to the Reporting Person's continuing service through each vesting date. /s/ Kendra Fox, as Attorney-in-Fact for Patrick John Finn 2026-02-19